Crizotinib Hydrochloride: ATP-Competitive Inhibitor for ALK, c-Met, and ROS1 Kinase Research

Executive Summary: Crizotinib hydrochloride (SKU B3608, APExBIO) is an ATP-competitive small molecule inhibitor with high selectivity for ALK, c-Met, and ROS1 kinases, and is validated for research into oncogenic signaling pathways [product]. It achieves low nanomolar inhibition of ALK and c-Met phosphorylation in vitro, making it a reference standard in kinase-driven cancer model systems [1]. Patient-derived assembloid models using Crizotinib hydrochloride enable detailed study of tumor–stroma interactions and drug resistance [1]. The compound demonstrates robust solubility in DMSO, ethanol, and water, and >98% purity (HPLC, NMR validated) [product]. Its standardized use enhances reproducibility and mechanistic clarity in cancer biology research [2].

Biological Rationale

Crizotinib hydrochloride is designed to inhibit aberrant kinase activity implicated in oncogenesis. ALK, c-Met, and ROS1 are receptor tyrosine kinases (RTKs) whose dysregulation via mutation, amplification, or translocation drives several tumor types, including gastric, lung, and anaplastic large cell lymphomas [1]. Oncogenic ALK fusions such as NPM-ALK, and overexpression of c-Met, are associated with tumor progression, poor prognosis, and drug resistance [1]. Targeted inhibition of these kinases disrupts downstream signaling (e.g., PI3K/AKT, MAPK pathways), curbing cancer cell proliferation and survival. Crizotinib hydrochloride thus directly addresses kinase-driven oncogenic processes relevant in both preclinical and translational cancer research.

Mechanism of Action of Crizotinib hydrochloride

Crizotinib hydrochloride is an orally available ATP-competitive inhibitor that binds to the catalytic domain of ALK, c-Met, and ROS1 kinases with high affinity, preventing ATP binding and subsequent tyrosine phosphorylation. In vitro, it reduces the phosphorylation status of c-Met and NPM-ALK fusion proteins at concentrations below 100 nM [product]. This inhibition halts autophosphorylation-dependent activation and downstream signaling cascades, including those regulating cell growth and survival. The compound's specificity enables selective disruption of oncogenic kinase pathways while minimizing off-target effects. In cell-based models, Crizotinib hydrochloride has been shown to decrease oncogenic signaling, induce apoptosis, and reduce proliferation rates in kinase-driven tumor cells [3]. The compound's ability to target multiple kinases (ALK, c-Met, ROS1) broadens its applicability to various molecularly defined cancers.

Evidence & Benchmarks

• Crizotinib hydrochloride inhibits ALK and c-Met phosphorylation in vitro at low nanomolar concentrations, validated by HPLC and NMR analyses (>98% purity) (Shapira-Netanelov et al., 2025).
• In patient-derived gastric cancer assembloids, Crizotinib hydrochloride modulates drug response and enables the study of tumor–stroma interactions (Shapira-Netanelov et al., 2025).
• The compound is soluble at ≥100.4 mg/mL in DMSO, ≥101.4 mg/mL in ethanol, and ≥52.2 mg/mL in water, allowing flexible formulation for in vitro and ex vivo models (APExBIO).
• Purity is consistently above 98%, as confirmed by HPLC and NMR, ensuring experimental reproducibility (APExBIO).
• Crizotinib hydrochloride is a standard tool for dissecting kinase-driven resistance mechanisms in advanced assembloid and organoid platforms ([4]).

This article updates and extends previous coverage by providing new patient-derived assembloid benchmarks and clarifying solubility and purity parameters.

Applications, Limits & Misconceptions

Crizotinib hydrochloride is widely used in cancer biology research to interrogate kinase-driven oncogenic signaling, mechanisms of drug resistance, and the impact of tumor microenvironmental factors. It is particularly useful in patient-derived assembloid and organoid models, where it enables functional drug screening and mechanistic studies. As a well-characterized ATP-competitive inhibitor, it facilitates the analysis of ALK, c-Met, and ROS1 pathways in diverse cellular contexts [5].

For deeper mechanistic insights, see the thought-leadership piece Crizotinib Hydrochloride in Patient-Derived Assembloids, which this article extends with new benchmarks in gastric cancer assembloid systems.

Common Pitfalls or Misconceptions

• Not effective in kinase-negative tumor models: Crizotinib hydrochloride does not inhibit tumors lacking ALK, c-Met, or ROS1 activation.
• Not a pan-kinase inhibitor: Its selectivity profile does not extend to unrelated kinases; off-target effects are minimal at research concentrations.
• Not suitable for long-term solution storage: Solutions may degrade if stored for extended periods at room temperature; store at -20°C and prepare fresh aliquots as needed.
• Not interchangeable with non-ATP-competitive inhibitors: Mechanistic outcomes differ between ATP-competitive and allosteric inhibitors; results are context-dependent.
• Not an FDA-approved therapeutic for all cancers: Research use only; clinical activity is restricted to specific molecularly defined cases.

Workflow Integration & Parameters

Crizotinib hydrochloride is supplied as a crystalline powder (CAS 1415560-69-8; MW 486.8 g/mol; formula C₂₁H₂₃Cl₃FN₅O). Prepare stock solutions at ≥100.4 mg/mL in DMSO, ≥101.4 mg/mL in ethanol, or ≥52.2 mg/mL in water. Store solids and aliquots at -20°C; avoid repeated freeze-thaw cycles. Experimental working concentrations typically range from 10–500 nM in cell-based assays, depending on model sensitivity and endpoint. For patient-derived assembloid models, pre-screen with titration assays to determine optimal inhibitory concentration. Quality control is ensured by HPLC and NMR, with batch-to-batch purity above 98% [APExBIO]. For further protocol details, consult this guide, which this article clarifies by providing updated storage and usage parameters for B3608.

Conclusion & Outlook

Crizotinib hydrochloride (APExBIO B3608) remains a cornerstone tool for dissecting ALK, c-Met, and ROS1 kinase signaling in cancer research. Its validated high purity, broad solubility, and ATP-competitive mechanism enable advanced studies in patient-derived assembloid models, illuminating drug resistance and tumor–stroma interactions. Ongoing research is extending its utility in precision oncology and in the optimization of combination therapies [1]. For current specifications and ordering, refer to the product page.